Key facts: Merck to Acquire Cidara for $9.2 Billion; Boosts Antiviral Pipeline
Less than 1 min read
- Merck & Co. is acquiring Cidara Therapeutics for $9.2 billion, paying $221.50 per share, a 108.9% premium. This deal enhances Merck's respiratory portfolio ahead of Keytruda's patent expiration.123
- Merck & Co. plans a $9.2 billion acquisition to boost its pipeline with a late-phase antiviral for flu prevention, expected to close in early 2026, pending approvals.4